ENTRADA THERAPEUTICS, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
ENTRADA THERAPEUTICS, INC. (TRDA) had Lessee, Operating Lease, Liability, to be Paid, Year One of $8.11 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-02-26
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $8.11M.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $12.05M.
- 2023-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $13.08M.
- 2023-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $13.10M.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $8.11M 10-K · filed 2026-02-26 |
| 2024-12-31 | $12.05M 10-K · filed 2025-02-27 |
| 2023-12-31 | $13.08M 10-K · filed 2024-03-13 |
| 2023-09-30 | $13.10M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $13.94M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $6.63M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $9.22M 10-K · filed 2023-03-06 |
| 2022-09-30 | $9.22M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $9.22M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $9.22M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $8.53M 10-K · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |